Lin Yu
Sichuan University
26 Papers
55 Citations
Lin Yu is an academic researcher from Sichuan University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 8, co-authored 21 publications.
Chat about Author
Papers
Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yuqin Yao,Lin Yu,Xiaolan Su,Yuxi Wang,Wenting Li,Yangpin Wu,Xiangzheng Cheng,Hang Zhang,Xian Wei,Hao Chen,Rundong Zhang,Lantu Gou,Xiaoxin Chen,Yongmei Xie,Bo Zhang,Yonghui Zhang,Jinliang Yang,Yuquan Wei +17 more
TL;DR: Three kinds of linkers were designed to connect SN-38, the bioactive metabolite of the anticancer drug irinotecan, with the anti-HER2 antibody trastuzumab to prepare three different ADC conjugates (T-SN38 A, B and C), which have great potential for HER2-positive ovarian cancer.
34
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Yiran Tao,Ruixue Wang,Qinhuai Lai,Mengdan Wu,Yuxi Wang,Xiaohua Jiang,Lishi Zeng,Shijie Zhou,Zhongping Li,Tinghan Yang,Yuqin Yao,Yangping Wu,Lin Yu,Yuyin Fu,Weirong Lai,Yujia Peng,Ying Lu,Zhixiong Zhang,Cuiyu Guo,Guangbing Zhang,Lantu Gou,Jinliang Yang +21 more
TL;DR: T4H11‐DM4, an ADC targeting DDR1 which carries the tubulin inhibitor payload DM4, highlights the potential of DDR1‐targeted ADC and may facilitate the development of a new effective therapeutic strategy for colon cancer.
31
Eradication of Growth of HER2-Positive Ovarian Cancer With Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate in Mouse Xenograft Model
Lin Yu,Yuxi Wang,Yuqin Yao,Wenting Li,Qinhuai Lai,Jun Li,Yongjun Zhou,Tai-Ran Kang,Yongmei Xie,Yangping Wu,Xiangzhen Chen,Cheng Yi,Lantu Gou,Jinliang Yang +13 more
TL;DR: The data showed that T-DM1 possessed promising antitumor effects on HER2-overexpressing ovarian cancer in mouse model, which provided valuable references for the future clinical trials.
30
Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
Qinhuai Lai,Mengdan Wu,Ruixue Wang,Weirong Lai,Yiran Tao,Ying Lu,Yuxi Wang,Lin Yu,Ruirui Zhang,Yujia Peng,Xiaohua Jiang,Yuyin Fu,Xin Wang,Zhixiong Zhang,Cuiyu Guo,Wei Liao,Yiwen Zhang,Tai-Ran Kang,Hao Chen,Yuqin Yao,Lantu Gou,Jinliang Yang +21 more
TL;DR: It is demonstrated that trastuzumab-CR55 conjugates have the potential for tumor targeted therapy, which provides insights to further research the CR55/CR52-based ADC for tumor therapy.
25
•Journal Article
A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.
Ruixue Wang,Qinhuai Lai,Liangze Tang,Yiran Tao,Yuqin Yao,Yu Liu,Ying Lu,Chaoyong Shen,Ran Lu,Chuanwen Fan,Ruirui Zhang,Yuxi Wang,Lin Yu,Tinghan Yang,Yangping Wu,Yujia Peng,Xian Wei,Xian Wei,Yuyin Fu,Weirong Lai,Lantu Gou,Jinliang Yang +21 more
TL;DR: In this article, the authors developed a novel anti-5T4 monoclonal antibody with high affinity and robust internalization ability and conjugated it to the potent microtubule inhibitor DM4 to produce conjugate H6-DM4.
17